CBR Division, Dstl Porton Down, Salisbury, United Kingdom.
ioGenetics LLC, Madison, WI, United States of America.
PLoS One. 2018 Oct 8;13(10):e0200213. doi: 10.1371/journal.pone.0200213. eCollection 2018.
Francisella tularensis is an intracellular pathogen causing the disease tularemia, and an organism of concern to biodefence. There is no licensed vaccine available. Subunit approaches have failed to induce protection, which requires both humoral and cellular immune memory responses, and have been hampered by a lack of understanding as to which antigens are immunoprotective. We undertook a preliminary in silico analysis to identify candidate protein antigens. These antigens were then recombinantly expressed and encapsulated into glucan particles (GPs), purified Saccharomyces cerevisiae cell walls composed primarily of β-1,3-glucans. Immunological profiling in the mouse was used to down-selection to seven lead antigens: FTT1043 (Mip), IglC, FTT0814, FTT0438, FTT0071 (GltA), FTT0289, FTT0890 (PilA) prior to transitioning their evaluation to a Fischer 344 rat model for efficacy evaluation. F344 rats were vaccinated with the GP protein antigens co-delivered with GP-loaded with Francisella LPS. Measurement of cell mediated immune responses and computational epitope analysis allowed down-selection to three promising candidates: FTT0438, FTT1043 and FTT0814. Of these, a GP vaccine delivering Francisella LPS and the FTT0814 protein was able to induce protection in rats against an aerosol challenge of F. tularensis SchuS4, and reduced organ colonisation and clinical signs below that which immunisation with a GP-LPS alone vaccine provided. This is the first report of a protein supplementing protection induced by LPS in a Francisella vaccine. This paves the way for developing an effective, safe subunit vaccine for the prevention of inhalational tularemia, and validates the GP platform for vaccine delivery where complex immune responses are required for prevention of infections by intracellular pathogens.
土拉弗朗西斯菌是一种细胞内病原体,可引起土拉菌病,是生物防御的关注对象。目前尚无许可的疫苗可用。亚单位方法未能诱导保护,这需要体液和细胞免疫记忆反应,并且由于缺乏对哪些抗原具有免疫保护作用的了解而受到阻碍。我们进行了初步的计算机分析,以确定候选蛋白抗原。然后将这些抗原重组表达并封装到葡聚糖颗粒(GP)中,葡聚糖颗粒是由主要由β-1,3-葡聚糖组成的纯化酿酒酵母细胞壁。在小鼠中进行免疫分析以进行向下选择,得到七种主要抗原:FTT1043(Mip)、IglC、FTT0814、FTT0438、FTT0071(GltA)、FTT0289、FTT0890(PilA),然后将其评估转移到 Fischer 344 大鼠模型中进行功效评估。用 GP 蛋白抗原与装载 Francisella LPS 的 GP 共给药对 F344 大鼠进行疫苗接种。测量细胞介导的免疫反应和计算表位分析允许进一步选择三种有前途的候选物:FTT0438、FTT1043 和 FTT0814。在这些候选物中,一种 GP 疫苗,其携带 Francisella LPS 和 FTT0814 蛋白,能够在大鼠中诱导对土拉弗朗西斯菌 SchuS4 的气溶胶挑战的保护,并降低器官定植和临床症状,低于单独使用 GP-LPS 免疫接种提供的保护。这是 LPS 补充 Francisella 疫苗诱导的保护作用的第一个报告。这为开发预防吸入性土拉菌病的有效、安全的亚单位疫苗铺平了道路,并验证了 GP 平台在需要复杂免疫反应来预防细胞内病原体感染的疫苗接种中的应用。